Magnera enters the second half of fiscal 2026 having quietly turned a loss-making, debt-laden combine into a company that generates real cash. The third quarter, which ended in late June, produced a return to operating profit and an adjusted free cash flow yield above 25 percent over the trailing twelve months, a print the management team framed as a record for the business. The equity now trades at a steep discount to that cash generation. The share price sits near $11.50. The enterprise value, roughly $2.1 billion, prices the guided adjusted EBITDA of $395 million at a multiple in the low 5x range. That combination of a low multiple and a high yield is the entire reason this stock attracts attention.
The catch is the balance sheet. The merger that created Magnera loaded the company with close to $2 billion of debt to fund a cash distribution to the former parent, and that debt consumes most of the operating profit each year. Net leverage near 4.8x is not a figure that supports aggressive capital recycling. The path to meaningfully lower it is slow, with free cash flow guided at $90 million to $110 million each year. The investment case therefore hinges on whether the cost program called Project Core keeps cutting expenses, whether organic volume in Europe and South America stops dragging, and whether the material weakness in the company's internal controls gets remediated before it erodes lender and investor confidence.
The strongest argument in favor is that the underlying products are consumer staples, wipes, incontinence items, and tea bags that sell in a recession just as they sell in a boom, and that the merger gave Magnera a scale it could never have built organically. The strongest argument against is that the debt load and the unresolved control deficiency leave very little margin for error. Free cash flow is the variable that resolves the debate, because every dollar of excess cash retires debt, and every dollar of debt retired shrinks the interest bill that currently keeps the bottom line in the red.